Alpha Cognition Inc
ACOG
Hisse Senetlerindeki Sıralama
#20189
Alpha Cognition Inc., a biopharmaceutical company, engages in the development... Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Hisse Fiyatı
$8.47
Son senkronizasyon: 2026-10-19
Piyasa Değeri
$131.47M
Değişim (1 gün)
3.36%
Değişim (1 yıl)
68.29%
Ülke
US
Ticaret Alpha Cognition Inc (ACOG)
Kategori
Healthcare
Alpha Cognition Inc (ACOG) için kazanç
Jun 2026 itibarıyla kazanç TTM: 0.00
Alpha Cognition Inc şirketinin en son finansal raporlarına göre, mevcut kazancı 0.00'dir. 2022 yılında şirket $-12.11M kazanç elde etti, bu 2021 yılındaki $-19.55M kazanca göre önceki yıla göre artış. Bu sayfada gösterilen kazanç, faiz ve vergiler öncesi kazançtır; yani EBIT.
Alpha Cognition Inc için kazanç geçmişi 2018 - 2026
Her yılın sonundaki kazanç
| Yıl | Kazanç | Değiştir |
|---|---|---|
| 2026 (TTM) | 0.00 | -100.00% |
| 2023 | $-13.77M | 13.68% |
| 2022 | $-12.11M | -38.02% |
| 2021 | $-19.55M | 237.90% |
| 2020 | $-5.78M | -12.45% |
| 2019 | $-6.61M | 20,254.71% |
| 2018 | $-32.46K | 0.00% |
Benzer şirketler veya rakipler için kazanç
| Şirket | Kazanç | Kazanç Farkı | Ülke |
|---|---|---|---|
| $5.27B | - |
US
|
|
| $-3.09B | - |
US
|
|
| $-4.02B | - |
AU
|
|
| - | - |
CH
|
|
| $1.95B | - |
NL
|
